crossMark
click for updates

A Phase-Variable Surface Layer from the Gut Symbiont *Bacteroides thetaiotaomicron*

Mao Taketani,[a,b] Mohamed S. Donia,[a]* Amy N. Jacobson,[a] John D. Lambris,[c] Michael A. Fischbach[a]

Department of Bioengineering and Therapeutic Sciences and California Institute for Quantitative Biosciences, University of California, San Francisco, San Francisco, California, USA[a]; Graduate Group in Infectious Diseases and Immunity, School of Public Health, University of California, Berkeley, Berkeley, California, USA[b]; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA[c]

* Present address: Mohamed S. Donia, Department of Molecular Biology, Princeton University, Princeton, New Jersey, USA.

ABSTRACT The capsule from *Bacteroides*, a common gut symbiont, has long been a model system for studying the molecular mechanisms of host-symbiont interactions. The *Bacteroides* capsule is thought to consist of an array of phase-variable polysaccharides that give rise to subpopulations with distinct cell surface structures. Here, we report the serendipitous discovery of a previously unknown surface structure in *Bacteroides thetaiotaomicron*: a surface layer composed of a protein of unknown function, BT1927. BT1927, which is expressed in a phase-variable manner by ~1:1,000 cells in a wild-type culture, forms a hexagonally tessellated surface layer. The BT1927-expressing subpopulation is profoundly resistant to complement-mediated killing, due in part to the BT1927-mediated blockade of C3b deposition. Our results show that the *Bacteroides* surface structure is capable of a far greater degree of structural variation than previously known, and they suggest that structural variation within a *Bacteroides* species is important for productive gut colonization.

IMPORTANCE Many bacterial species elaborate a capsule, a structure that resides outside the cell wall and mediates microbe-microbe and microbe-host interactions. Species of *Bacteroides*, the most abundant genus in the human gut, produce a capsule that consists of an array of polysaccharides, some of which are known to mediate interactions with the host immune system. Here, we report the discovery of a previously unknown surface structure in *Bacteroides thetaiotaomicron*. We show that this protein-based structure is expressed by a subset of cells in a population and protects *Bacteroides* from killing by complement, a component of the innate immune system. This novel surface layer protein is conserved across many species of the genus *Bacteroides*, suggesting an important role in colonization and host immune modulation.

Address correspondence to Michael A. Fischbach, fischbach@fischbachgroup.org.

Bacteria elaborate a broad array of capsules, structures that reside outside the cell wall and play roles in adhesion and immune modulation (1, 2). The capsular polysaccharides (CPSs) produced by species of *Bacteroides*, the dominant bacterial genus in the human gut (3–5), have served as a model system for understanding the role of the capsule in host-symbiont interactions (6). *Bacteroides fragilis* produces eight distinct capsular polysaccharides, PSA to PSH; with the exception of PSC, each is expressed in a phase-variable manner by a reversible inversion of repeat segments flanking the promoter of each polysaccharide locus (7). The configuration of the invertible CPS promoters is governed by a global Mpi (multiple-promoter invertase) from the Ssr family (8) as well as by enzymes in the Tsr family that are specific to the promoter in their immediate downstream region (9); UpxY family transcriptional antitermination factors and UpxZ family inhibitors block the simultaneous expression of two or more polysaccharides (10, 11). The capacity to produce multiple phase-variable CPSs with limited concurrent polysaccharide synthesis processes creates subpopulations of diverse surface structures and antigenicities that are thought to play an important role in the ability of *Bacteroides* to colonize the gastrointestinal (GI) tract (12–14). In light of the discoveries of immunomodulatory properties of one of the CPSs, polysaccharide A in *Bacteroides fragilis* (2, 6), we sought to determine whether there exist previously unknown surface structures in *Bacteroides* that may have other immunomodulatory properties.

RESULTS AND DISCUSSION

Serendipitous discovery of a cryptic surface layer protein in *Bacteroides*. We began by systematically searching *Bacteroides* genome sequences for gene clusters predicted to encode factors that mediate microbe-host interactions (15). Three such gene clusters in *Bacteroides thetaiotaomicron* VPI-5482 (*B. thetaiotaomicron 1949* [*BT1949*] to *BT1954*, *BT2093* to *BT2095*, and *BT4420* to *BT4430*) were predicted to contain genes that encode surface layer proteins, which vary widely in composition among microbial taxa but are known to play a role in processes central to microbe-host interaction, including biofilm formation, adhesion, and immune evasion (16). To determine whether these loci specify the production of a surface layer, we constructed strains in which *BT1954*,

FIG 1 A phase-variable surface layer protein in *B. thetaiotaomicron*. (A) Proteins were precipitated from filtered culture supernatants of *B. thetaiotaomicron* (*Bt*) with trichloroacetic acid and subjected to SDS-PAGE. The Δ*BT1954* strain culture supernatant harbors an abundant, high-molecular-mass band that is absent in *B. thetaiotaomicron* (see also Fig. S1 in the supplemental material). (B) *B. thetaiotaomicron* cells were fixed, cut into ultrathin sections, negative stained, and imaged through the use of a transmission electron microscope. The Δ*BT1954* mutant (upper right and lower right) harbors a tessellated surface layer, adjacent to the outer membrane, which is absent in the parental strain (upper left and lower left). Each scale bar represents 100 nm. (C) Schematic of the *BT1927*-to-*BT1929* locus, showing inverted repeat elements flanking the predicted *BT1927* promoter. SS, site specific. (D) Schematic of the promoter orientation assay. DrdI-digested PCR products were separated by agarose gel electrophoresis. The inverted repeat element harboring the predicted *BT1927* promoter is in opposite orientations in the parental strain and the Δ*BT1954* mutant (see also Fig. S1).

BT2095, or the entire *BT1949*-to-*BT1957* locus was deleted. We then compared cell surface protein preparations of *B. thetaiotaomicron* and the mutants by SDS-PAGE, expecting to find a cell surface protein(s) that was present in the *B. thetaiotaomicron* preparation but missing from one or more of the mutants. No such proteins were found, but, to our surprise, we found reproducibly that one of the mutants, the Δ*BT1954* strain, expressed very high levels of a new cell surface protein (Fig. 1A).

Transmission electron micrographs (EM) of the Δ*BT1954* mutant revealed a novel surface structure that resembles a crystalline surface layer. The hexagonal lattice extends ~500 Å beyond the outer membrane, and it appears to cover in a monolayer the entire length of the rod as well as both of its ends (Fig. 1B). We could not conclude from the EM images whether these mutants retain the electron-dense layer of capsular polysaccharides (17) characteristic of *B. thetaiotaomicron*.

As a proteinaceous surface layer has not yet been described in

Bacteroides, we set out to determine the identity of its constituent protein(s). Cell-free culture fluid from log-phase Δ*BT1954* mutant cells was acidified to precipitate proteins that were secreted or had dissociated from the cell material. We separated the proteins using denaturing polyacrylamide gel electrophoresis, and the most prominent band (apparent molecular mass = ~100 kDa) was excised and subjected to tandem mass spectrometry. Multiple peptide matches confirmed that it was BT1927, a 928-amino-acid (aa) protein of unknown function. (We suspect that the N terminus is annotated incorrectly in the database, as an earlier start codon would include an additional 12 amino acids that are highly conserved in the orthologs of BT1927. Residue numbers throughout the manuscript refer to the corrected open reading frame [ORF].) Although a related species of a different family of *Bacteroidales* (also a member of the human microbiota), *Parabacteroides distasonis* 8503, has been reported to possess a phase-variable S-layer glycoprotein (18), the unambiguous

FIG 2 Construction and characterization of *BT1927*-ON and *BT1927*-OFF mutants. (A) One half-site of the inverted repeat surrounding the predicted *BT1927* promoter was mutated to create strains in which this element could no longer flip, "locking" the expression of *BT1927* on (*BT1927*-ON) or off (*BT1927*-OFF). (B) Cells of the *BT1927*-OFF (upper left and lower left) and *BT1927*-ON (upper right and lower right) mutants were prepared as described in the Fig. 1 legend and visualized by transmission electron microscopy, confirming the presence of the same surface structure in *BT1927*-ON that was observed in the Δ*BT1954* mutant. Each scale bar represents 100 nm (see also Fig. S2 in the supplemental material).

identification of a crystalline surface layer in a *Bacteroides* species is unprecedented.

Expression of *BT1927* is controlled by an invertible promoter. *BT1927* resides in a locus adjacent to two site-specific recombinases, *BT1928* and *BT1929*, and the 887 bp of intergenic sequence between *BT1927* and *BT1928* contains a 256-bp predicted promoter-containing element flanked by 22-bp inverted repeats (IRs) (Fig. 1C) (19). Similar invertible promoter elements are responsible for the phase-variable expression of other surface structures, including capsular polysaccharides (7–9, 18), indicating that the expression of this new type of surface structure might be controlled by a mechanism similar to that of the well-characterized capsular polysaccharides. Consistent with this view, a previously reported analysis of DNA sequencing reads from *Bacteroides fragilis* NCTC 9343 has shown that a promoter of similar architecture that resides adjacent to *BF4087*, a homolog of *BT1927*, exists in both orientations under conditions of laboratory culture and that the promoter's orientation is controlled by the recombinase Tsr26, a homolog of *BT1928* and *BT1929* (9). In order to determine the orientation of the *BT1927* promoter in the Δ*BT1954* mutant, we amplified the IR element with primers that anneal beyond its 5′ and 3′ borders and digested the amplicon with the restriction enzyme DrdI, which has a recognition site inside the element that generates asymmetric fragments that are diagnostic of orientation (Fig. 1D). We found that in *B. thetaiotaomicron*, the promoter exists in one orientation (OFF, as described below), but in the Δ*BT1954* mutant, the opposite orientation of the promoter is observed (ON, as described below) (Fig. 1D).

As the BT1927 locus operon is >36 kb away from BT1954, we next sought to determine whether BT1927 is related to BT1954. Two lines of evidence suggest that there is no direct relationship between the two proteins. (i) We rederived the Δ*BT1954* mutant from the merodiploid (single-crossover) intermediate; none of the rederived mutants harbored the *BT1927* promoter in the ON configuration. (ii) We independently constructed mutants in which the expression of *BT1927* was "locked" on or off by mutating one of the half-sites of its invertible promoter (Fig. 2A; here, *BT1927*-ON and *BT1927*-OFF), and neither mutant harbored a polymorphism at the *BT1954* locus. We conclude that (i) our initial Δ*BT1954* mutant underwent a rare bottleneck event in which a *BT1927*-expressing variant was inadvertently isolated; (ii) *BT1927* is unrelated to *BT1954*, although we cannot rule out the possibility of a high-level regulatory connection between the two loci; and (iii) our discovery of *BT1927* was serendipitous. We therefore performed the rest of our experiments with the *BT1927*-ON and *BT1927*-OFF mutants, and *BT1954* was not investigated further.

BT1927 is secreted and localized to the cell surface. We next sought to determine unambiguously that the BT1927 protein product is secreted and localized to the cell surface. The N terminus of BT1927 harbors a predicted signal peptide, and peptides from trypsin- and ArgC-digested BT1927 start with T26, suggesting that the protein is cleaved after D25 during the process of secretion. Three bioinformatic findings provided further evidence for the secretion of BT1927. (i) The N-terminal 48 aa of BT1927 are highly conserved across its homologs in *Bacteroides* spp. (75% to 100%), but the remaining 880 aa are less so (31% to 43%), indicating a conserved function for its putative N-terminal signal

FIG 3 BT1927 is expressed in a subpopulation of *B. thetaiotaomicron*. (A) *BT1927*-ON-FLAG and *BT1927*-OFF-FLAG cells were washed, stained with an anti-FLAG antibody conjugated to Alexa 647 and the DNA stain SYTO BC, and visualized by fluorescence microscopy. Cell surface staining in the *BT1927*-ON-FLAG mutant but not the *BT1927*-OFF-FLAG mutant is consistent with localization of BT1927 to the cell surface. Each scale bar represents 2 μm. (B) *BT1927*-ON-FLAG, *BT1927*-OFF-FLAG, and *BT1927*-FLAG cells were washed, stained as described above, and analyzed by flow cytometry to measure the frequency of BT1927-expressing cells in each culture. As expected, the BT1927-expressing population (upper right quadrant) dominated the *BT1927*-ON culture and was nearly absent in the *BT1927*-OFF culture. The *BT1927*-FLAG culture reproducibly showed a BT1927-expressing subpopulation that represented ~1:1,000 cells in the population. (C) The frequency of the two promoter orientations of a *BT1927* ortholog in a whole-genome shotgun metagenomic sequence sample from the NIH Human Microbiome Project was measured by recruiting raw sequence reads to each promoter orientation. A total of 92% of the reads were recruited to one (presumably OFF) orientation, and the remaining 8% of the reads were recruited to the opposite (presumably ON) orientation, suggesting that the BT1927-expressing cells might exist at a higher frequency *in vivo* than *in vitro*.

peptide (see Fig. S1A, Fig. S3, and Text S3 in the supplemental material). (ii) The conserved N-terminal peptide extends longer than a typical signal peptide, suggesting a function beyond that of a typical signal peptide (see Fig. S1B). (iii) BT1927 and its homologs are found in a location adjacent to a gene that encodes a predicted outer membrane beta-barrel protein, consistent with the combination of BT1927 and BT1926 (BT1927-BT1926) (and its orthologs) functioning as a two-partner secretion system (see Text S1 and Text S2 in the supplemental material).

Three lines of experimental evidence suggest that BT1927 is present on the cell surface. First, SDS-PAGE analysis of trichloroacetic acid (TCA)-precipitated proteins from cell-free culture fluid revealed a high-molecular-mass band in the *BT1927*-ON cells but not the *BT1927*-OFF cells; this band corresponds to BT1927 and is the same band that appeared in the Δ*BT1954* mutant (see Fig. S2 in the supplemental material). Second, transmission electron micrographs of the *BT1927*-ON mutant show the

same tessellated structure adjacent to the outer membrane as in the Δ*BT1954* mutant, but this structure is absent in the *BT1927*-OFF mutant (Fig. 2B). Finally, we constructed mutants in the *BT1927*-ON and *BT1927*-OFF backgrounds in which a FLAG tag was appended in frame to the C terminus of BT1927. Immunocytochemical staining of *BT1927*-ON-FLAG and *BT1927*-OFF-FLAG cells confirmed that BT1927 is present on the surface of the former but not the latter mutant (Fig. 3A). Together, these results suggest that BT1927 is secreted through the inner and outer membranes, forming a novel surface structure adjacent to the outer membrane.

A subpopulation of a wild-type *B. thetaiotaomicron* culture expresses BT1927. Having validated that *BT1927*-ON cells harbor a novel surface layer, we next asked what percentage of cells in a laboratory culture of *B. thetaiotaomicron* express BT1927. Because we were able to detect cells with the *BT1927* promoter in the ON orientation using PCR amplification but not the PCR-based re-

striction digestion assay described above, we hypothesized that BT1927-expressing cells occur at a low frequency, requiring us to develop a more sensitive method of detection. Having previously constructed *B. thetaiotaomicron* mutants in which BT1927 is C-terminally FLAG tagged in the *BT1927*-ON and *BT1927*-OFF backgrounds, we next constructed a mutant in which BT1927 is C-terminally FLAG tagged in the parental *B. thetaiotaomicron* background (here, *BT1927*-FLAG). Cells from all three of the *BT1927*-FLAG strains were labeled with a monoclonal anti-FLAG antibody, and FLAG-positive (FLAG[+]) cells were quantified by flow cytometry. As expected, 93.2% to 97.1% of the cells in the *BT1927*-ON-FLAG population had detectable BT1927 expression, while expression in *BT1927*-OFF-FLAG cells was 0.04% to 0.08%. In a culture of *BT1927*-FLAG, we found reproducibly that 0.15% to 0.25% of the cells expressed BT1927, suggesting that cells expressing the surface layer form a minority of ~1:1,000 cells in a laboratory population of *B. thetaiotaomicron* (Fig. 3B).

The frequency of phase variants under conditions of laboratory culture is known to differ from that seen under conditions of growth in an animal host (20, 21). To determine the frequency of this phase variant *in vivo*, we next analyzed whole-genome-shotgun (WGS) metagenomic sequence data from Human Microbiome Project (HMP) stool samples in an effort to find a subject colonized predominantly by *B. thetaiotaomicron*. Although we found *BT1927* in 52 (60%) of 86 stool samples, its coverage in those samples was not deep enough to detect both orientations. Instead, we found a subject colonized at a high level by a strain of *Bacteroides fragilis* that harbors a homolog of BT1927. We computationally recruited raw reads from this WGS sample to four loci corresponding to the two orientations of the invertible promoter; an average of 22 reads (~8% of total reads) were recruited to one orientation (presumably ON), while an average of 254 reads (~92% of total reads) were in the opposite orientation (presumably OFF). In order to compare this result to the frequency of each orientation in *B. fragilis* cultivated *in vitro*, we performed targeted amplicon sequencing on a region that encompasses the predicted invertible sites, including the *B. fragilis* ortholog of the *BT1927* promoter. We used *B. fragilis* strain 638r, which harbors a *BT1927* ortholog that is 100% identical at the nucleotide level to the *B. fragilis* locus found in the metagenomic data described above. From our data, we were able to recruit 74 reads to one orientation of the *BT1927* ortholog promoter region (presumably ON; 0.008%) and 910,786 reads to the other orientation (presumably OFF; 99.992%) (see Table S2 and Text S3 in the supplemental material). This finding indicates that the frequency of BT1927 ortholog expression may be higher *in vivo* than *in vitro* (Fig. 3C).

BT1927-ON cells are resistant to complement-mediated killing. Finally, we turned to the issue of whether the *B. thetaiotaomicron* subpopulation expressing a surface layer is functionally distinct from the majority of cells expressing a conventional polysaccharide capsule. To begin addressing this issue, we subjected the *BT1927*-ON and *BT1927*-OFF mutants to a set of assays relevant to colonization and growth in the mammalian gut: recognition by IgA, tropism in the small and large intestines, sensitivity to antimicrobial peptides, activation of TLR2 and TLR4, and sensitivity to lysis in serum.

Only one of these assays revealed a functional difference between *BT1927*-ON and *BT1927*-OFF: *BT1927*-ON cells were shown to be highly resistant to complement-mediated killing. When incubated with 20% human serum for 60 min, 48.18% ±

12% of the *BT1927*-ON cells survived compared to just 0.97% ± 0.18% of the *BT1927*-OFF cells (Fig. 4A); similar results were obtained by adjusting serum sources (human and rabbit) and concentrations. We note, however, that 20% human serum might be a superphysiological concentration of complement in the context of gut colonization.

To explore the molecular underpinnings of complement resistance in the BT1927-expressing subpopulation, we turned to the issue of what step in the complement cascade is blocked by BT1927-expressing cells. We tested the integrity of C3b deposition, a key step in the complement pathway that is known to be subverted by bacterial pathogens. We incubated the *BT1927*-ON and *BT1927*-OFF strains with human serum, labeled cells with fluorescein isothiocyanate (FITC)-conjugated anti-human C3 $F(ab')2$, and performed flow cytometry to assess the level of C3 fragments associated with bacterial cells. As shown in Fig. 4B and C, C3 or its fragments associated with *BT1927*-ON cells at a lower efficiency than and with delayed kinetics relative to *BT1927*-OFF cells. These results suggest that BT1927-mediated blockade of C3b deposition is at least partly responsible for the resistance of the BT1927-expressing subpopulation to complement-mediated killing.

Previous work has shown that surface layer proteins from pathogenic bacteria such as *Campylobacter fetus* confer resistance to complement-mediated lysis (22, 23), one of several strategies used by pathogens to evade the complement system (24). However, *B. thetaiotaomicron* is a symbiont, not a pathogen or pathobiont, and is therefore unlikely to encounter the complement system in serum. Recent studies suggested that complement regulates the composition of the skin and oral communities (25–27) and that complement components are deposited into the lumen and epithelial surface of the murine and human GI tract (28–34). However, more work is needed to determine whether there exists a physiologically relevant interaction between complement and the microbiota under conditions of colonization and, if so, what role, if any, the *B. thetaiotaomicron* surface layer plays in an interaction with the complement system.

Our data show that *Bacteroides* can remodel its surface to express a previously unknown surface layer, and they suggest that *Bacteroides* populations harbor a greater diversity of subpopulations with distinct surface structures than was previously known. The BT1927-expressing subpopulation might be able to colonize a different niche in the mammalian gut, although further studies are needed to explore this idea and determine the biological significance of the surface layer. Further study of other phase-variable loci might also reveal new subpopulations of cells with distinct functions that are important for colonization and microbe-host interactions.

MATERIALS AND METHODS

Bacterial strains, media, and growth conditions. All bacterial strains used in this study are listed in Table S1 in the supplemental material. All *Bacteroides thetaiotaomicron* strains were grown at 37°C in brain heart infusion (BHI) agar supplemented with 10% horse blood, tryptone-yeast extract-glucose (TYG) medium, or *Bacteroides* minimal medium (MM) (35, 36) in an anaerobic chamber (Coy Laboratory Products) with a 5% H_2, 20% CO_2, and N_2 (balance) gas mix. *Escherichia coli* strains were grown aerobically at 37°C in LB medium supplemented with ampicillin to select for the pExchange-*tdk* plasmid.

Construction of *Bacteroides thetaiotaomicron* mutants. All plasmids and primers are listed in Tables S1 and S2 in the supplemental

FIG 4 BT1927 confers resistance to complement-mediated killing. (A) *BT1927*-ON and *BT1927*-OFF cells were incubated in 10% or 20% human serum or 20% heat-inactivated serum at 37°C for 1 h, serially diluted, and plated. For each strain, the number of colonies that survived in untreated serum was counted and divided by the number of colonies that survived in BHI serum to determine the percentage of survival. In 20% serum, *BT1927*-ON cells were more resistant to serum-mediated lysis (48.18% ± 12% survival) than *BT1927*-OFF cells (0.97% ± 0.18% survival). *, $P < 0.05$ (Student's *t* test). (B) Approximately the same numbers of *BT1927*-ON and *BT1927*-OFF cells were incubated in 5%, 10%, 15%, or 20% serum at 37°C for 30 min, washed, stained with FITC-conjugated anti-C3 $F(ab')2$, and analyzed by flow cytometry. The bar graph shows the absolute numbers of events that were APC$^+$ and FITC$^-$ (intact cells not associated with C3 or a C3 fragment). C3 or its fragments associated at lower efficiency with *BT1927*-ON cells than with *BT1927*-OFF cells, consistent with a blockade of C3b deposition by BT1927. *, $P < 0.05$ (Student's *t* test). (C) The same experiment as that described for panel B was used to measure the distribution of FITC$^+$ (C3 fragment-associated) and FITC$^-$ (not C3 fragment-associated) populations in the *BT1927*-ON and *BT1927*-OFF mutants. Samples were treated with 10% serum for 30 min (top panel) or 60 min (bottom panel). The results, which are representative of three independent experiments, show that *BT1927*-ON cells appear to activate complement with delayed kinetics compared with the *BT1927*-OFF cells, as measured by the presence of the C3 fragment. max, maximum.

material. All mutants were created in the *B. thetaiotaomicron* VPI-5482 Δ*tdk* background, which is referred to in the text as "*B. thetaiotaomicron.*" The Δ*BT1954* mutant was constructed using the counterselectable allele exchange method described by Koropatkin and coworkers (37). Briefly, ~1-kb fragments upstream and downstream of the *BT1954* gene were cloned and fused using primer pairs Δ*BT1954* Sal-UF/UR and DF/XbaI-DR, respectively, and ligated into the suicide vector pExchange-*tdk* (obtained from Justin Sonnenburg, Stanford University). The resulting vector was electroporated into *Escherichia coli* S17-1 λ *pir* and then conjugated into *B. thetaiotaomicron.* Single recombinants were selected on BHI-blood agar plates containing 200 μg/ml gentamicin and 25 μg/liter erythromycin. Single recombinants were cultured in TYG medium overnight and then plated onto BHI-blood agar plates containing 200 μg/ml 5-fluoro-2-deoxyuridine (FUdR). Candidate *BT1954* deletions were screened by PCR using the diagnostic primers listed in Table S2 and confirmed by DNA sequencing to identify isolates that had lost the gene.

BT1927-ON and *BT1927*-OFF mutants were constructed using a strategy adapted from Gunther et al. (38). We used the counterselectable allele exchange method described above, except that the insertion ligated into pExchange-*tdk* was made by fusing three fragments: (i) a 1-kb upstream fragment, (ii) the promoter region (in ON or OFF orientation) flanked by one native IR sequence and one mutated IR sequence consisting of random DNA sequence, and (iii) a 1-kb downstream fragment. The random sequence was generated using a random DNA sequence generator (http://www.faculty.ucr.edu/~mmaduro/random.htm) with the addition of a BglII site to facilitate screening by restriction digestion.

The FLAG epitope tag was inserted in frame at the 3′ end of the *BT1927* coding sequence in the *BT1927*-ON and *BT1927*-OFF back-grounds using the method described above, except that the construct was made by fusing a 1-kb upstream fragment and a 1-kb downstream fragment harboring the FLAG sequence.

Diagnostic digestion to determine the orientation of the *BT1927* promoter region. The *BT1927* promoter region was amplified by PCR using primers *BT1927* IR1 and IR2 (see Table S2 in the supplemental material). The amplicon was cleaned using a Qiagen PCR purification kit and digested overnight with DrdI. The digested amplicon fragments were separated on a 1% agarose Tris-acetate-EDTA (TAE) gel and imaged using an Alpha Imager (Protein Simple).

Protein extraction and SDS-PAGE. The *B. thetaiotaomicron* wild-type, Δ*BT1954*, *BT1927*-ON, and *BT1927*-OFF strains were cultured overnight in TYG medium, diluted 1:100 in fresh TYG medium, and grown to log phase (~6.5 h) the next day. The culture supernatant was filtered using a 0.22-μm-pore-size syringe filter (Millipore) and concentrated using a 10K-molecular-weight-cutoff Amicon Ultra-15 centrifugal filter (Millipore), and proteins were precipitated by addition of 1 vol of a trichloroacetic acid stock solution (500 g trichloroacetic acid dissolved in 350 ml H_2O) to 4 vol of supernatant, followed by two cold acetone washes. The precipitate was resuspended in sample buffer and loaded onto a 10% acrylamide gel. Gels were stained with Coomassie blue for visualization and protein band excision.

Transmission electron microscopy sample preparation and imaging. (i) *B. thetaiotaomicron* culture and initial fixation. *B. thetaiotaomicron* and mutant strains were cultured overnight in TYG medium in the anaerobic chamber at 37°C. The following day, saturated cultures were diluted 1:50 into 10 ml MM for 15 h at 37°C in the anaerobic chamber. After 15 h, 7.5 ml 4% glutaraldehyde–MM was mixed with 7.5 ml of the

culture and fixed in the anaerobic chamber for 10 min with rocking. The mixture was centrifuged at $3,270 \times g$ for 10 min, and the pellet was resuspended in 2 ml 2.5% glutaraldehyde–0.1 M sodium cacodylate buffer at pH 7.2 (abbreviated as "CB"). The resulting suspension was divided into aliquots, added to microcentrifuge tubes, and stored at 4°C until further processing.

(ii) Washing and postfixation. For the remainder of the sample preparation procedure, all centrifugation steps were performed at ~21,000 × *g* for 1 min. The cell suspension in CB was centrifuged, and cells were resuspended in fresh CB and incubated for 10 min; this wash step was repeated for a total of 3 times. After the last wash step, the cells were resuspended in CB supplemented with 1% OsO_4 and 1.6% potassium ferricyanide. Using a Pelco Biowave Pro microwave tissue processor (Ted Pella; abbreviated as "MW"), the cells were fixed with 2 cycles of the following procedure: 2 min of heating in a vacuum and 2 min of vacuum without heating. To remove the OsO_4, the cells were resuspended in CB, heated for 40 s in the MW, and centrifuged, and the supernatant was removed. This wash step was repeated a total of 3 times.

(iii) Uranyl acetate en bloc staining. To remove salts, cells were washed three times by centrifugation, resuspended in deionized (DI) water, and incubated for 10 min at room temperature. Cells were resuspended in 1% uranyl acetate prepared in DI water and stained in the MW using 2 cycles of the following program: 2 min heating in a vacuum and 2 min of vacuum without heating. Uranyl acetate was removed by resuspension in DI water and heating at 40 s in the MW a total of 3 times.

(iv) Dehydration and infiltration. Dehydration consisted of the following procedure: centrifugation, resuspension of the cell pellet in 35% ethanol, and heating in the MW for 40 s. This process was repeated a total of 2 times each with 35%, 50%, 70%, 80%, 95%, and 100% ethanol, followed by one additional 40-s heating step with 100% ethanol and 40 s of heating with 100% acetone. The cells were pelleted, the acetone was decanted, and then the resin was infiltrated (recipe for 50 mg resin: 23.5 mg of Eponate 12 resin, 12.5 mg of dodecenyl succinic anhydride [DDSA], 14 mg of nadic methyl anhydride [NMA], and 0.75 ml of benzyldimethylamine [BDMA]) at an acetone/resin ratio of 3:1. This mixture was subjected to 2 cycles of 3 min of heating in a vacuum in the MW. The same procedure was repeated with a 1:1 mixture of acetone and resin and then a 1:3 mixture. Finally, cells were resuspended in pure resin, heated in a vacuum in the MW for 3 min, and then centrifuged; this final procedure was repeated a total of 3 times. Cells were placed in a beam capsule and heated in a 55°C oven for 2 days.

(v) Ultrathin sectioning and imaging. The resin-embedded cells were cut into ultrathin sections using a diamond knife. Sectioned samples were inserted into a Pelco grid staining system. Samples were stained in 2% methanolic uranyl acetate (2% uranyl acetate dissolved in 70% methanol–H_2O) for 5 min at room temperature, washed 5 times in DI water, and then stained in Reynolds lead citrate (recipe for 50 ml: 1.33 g lead nitrate and 1.76 g of sodium citrate dihydrate were dissolved in 30 ml DI H_2O; 8 ml of 1 N NaOH was added, followed by 10 ml of DI H_2O) for 5 min at room temperature. A total of 10 more washes were performed with DI water, and the sample was dried with a Kimwipe and imaged on an FEI Tecnai 12 transmission electron microscope. The images were cropped, and the size of each image was compressed using Adobe Photoshop. ImageJ was used to add the scale bar.

Immunofluorescent labeling and microscopy. Immunofluorescent labeling was performed according to a protocol described by Moyes (39). Briefly, bacteria were cultured in TYG medium overnight in the anaerobic chamber at 37°C. Saturated cultures were diluted 1:50 in 10 ml MM and incubated for 15 h at 37°C in the anaerobic chamber. Following incubation, cultures were centrifuged at $3,720 \times g$ for 10 min, washed with phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na_2HPO_4, 1.8 mM KH_2PO_4), and resuspended to approximately 10^7 to 10^8 CFU/ml. A smear was prepared by spreading 20 μl of the resuspended cells using a sterile loop on a clean microscope slide, and then the smear was air dried in the fume hood, submerged in 95% ethyl alcohol (EtOH),

and subjected to heat fixation by incubation in the 55°C oven for 10 min. Slides were incubated with an anti-FLAG antibody conjugated to Alexa Fluor 647 (Cell Signaling) (diluted 1:100 in PBS) for 30 min at 37°C, rinsed, and incubated in PBS for 30 min at room temperature. Labeled cells were counterstained with SYTO BC Bacteria Stain (Molecular Probes). Images were acquired using a 100× objective on a 6D high-throughput microscope at the Nikon Imaging Center of the University of California, San Francisco (UCSF). The images were cropped, and the size of each image was compressed using Adobe Photoshop. ImageJ was used to add the scale bar.

Flow cytometry to quantify BT1927-expressing cells. *B. thetaiotaomicron* and mutant strains were grown in TYG medium overnight, diluted 1:100 in fresh TYG medium, and grown to the late log phase (~6.5 h). One milliliter of the culture was centrifuged for 2 min in a microcentrifuge at $6,000 \times g$, washed twice with PBS, and resuspended to approximately 50×10^6 cells/ml in Bacteria Staining buffer (BSB; 1% bovine serum albumin–0.025% sodium azide–PBS). In a V-bottom 96-well cell culture plate (Corning), 25 μl of the resuspended bacteria was mixed with 25 μl anti-FLAG Alexa Fluor 647-conjugated antibody (Cell Signaling) (diluted 1:25 in BSB) and incubated for 1 h at 37°C. The 96-well plates were centrifuged at $3,273 \times g$ on a Beckman tabletop centrifuge for 4 min to pellet the cells and washed twice with 150 μl BSB. Cells were counterstained with SYTO BC Bacteria Stain (Molecular Probes) and analyzed on an LSRII flow cytometer. In order to minimize carryover of cells, 3 blank samples of PBS were included between samples. Forward scatter (FSC) and side scatter (SSC) data were set to logarithmic scale. Two populations (top and bottom) were visible on the FSC and SSC plots, where the bottom population was present even in sterile H_2O, bleach, and PBS without any bacteria and the top population was present only in samples with bacteria. Therefore, a gate was set to exclude the bottom population and 500,000 events were collected for the top population. After data acquisition, the top *B. thetaiotaomicron* population was visualized on an allophycocyanin (APC)-versus-FITC plot and further separated by quadrants, which were set using the unstained sample. Spectral overlap was calculated from single-stained controls. All postacquisition analyses and compensations were performed using FlowJo (Tree Star).

Computational analysis of *BT1927* and its orthologs in stool samples sequenced by the HMP. The protein sequence of BT1927 was used as a query sequence for BLASTp searches of a translated database of assembled contigs from each of the first-visit stool samples sequenced by the Human Microbiome Project (HMP) ($n = 86$; available at the HMP Data Analysis and Coordinating Center [DACC]). BT1927 was deemed "present" in a sample when a protein sequence was detected as a hit, with an expectation value of <1.0e-50. The relatively low coverage of *B. thetaiotaomicron* in these samples (~20× to ~30×, as determined by coverage calculation for the BT1927 inverted repeat region in a subset of these samples) prevented us from determining the orientation of the *BT1927* promoter region. We then performed a similar BLAST search to identify BT1927 orthologs from other *Bacteroides* spp. with high depth of coverage in the HMP samples. One sample, SRS016267, harbored a *B. fragilis* BT1927 ortholog at 477× coverage. Quality-filtered and trimmed reads of SRS016267 were obtained from the HMP DACC and used to determine the frequencies of both orientations of this gene's promoter. Briefly, we divided the inverted repeat/promoter region of the BT1927 ortholog into four sequence blocks of 100 bp, where each block consisted of 18 bp of each of the inverted repeats flanked by 41 bp on each side, to determine its orientation. Two blocks corresponded to the upstream and downstream inverted repeat sequences of orientation 1, and the other two blocks corresponded to the upstream and downstream inverted repeat sequences of orientation 2. SRS016267 reads matching these blocks were identified using BLASTn with a cutoff expectation value of 1.0e-31, which we determined to be necessary to unequivocally assign the orientation. To further confirm their orientation, these reads were mapped to the corresponding sequence blocks using Geneious (with the following parameters: minimum percent identity at overlap, 90%; maximum percentage of mismatch

per read, 20%), and the average coverage of each block was calculated only from the mapped reads.

Human complement killing assay. *B. thetaiotaomicron* and mutant strains were cultured overnight in TYG medium. The next day, cells were harvested by centrifugation, washed once with PBS, and resuspended to 50×10^6 CFU/ml in PBS^{++} (PBS supplemented with 0.5 mM MgCl$_2$ and 1 mM CaCl$_2$). Cells were incubated in human serum and heat-inactivated serum at various concentrations in PBS^{++} at 37°C for 1 h. Following incubation, cells were diluted and plated on BHI–10% horse blood agar plates and incubated anaerobically until colonies appeared. Percent survival was calculated by dividing the average number of colonies that appeared on each human serum plate by the average number of colonies that appeared on the heat-inactivated serum plate and multiplying by 100. Error bars represent the standard deviation. Student's *t* test was performed to calculate P values (*, $P < 0.05$).

Flow cytometry to determine C3 fragment presence in *BT1927*-ON and *BT1927*-OFF cells. *BT1927*-ON and *BT1927*-OFF cells were cultured overnight in TYG medium. Cells were pelleted and washed once with PBS, and approximately the same numbers of cells were incubated in 20% human serum–PBS^{++} for 30 to 60 min at 37°C. Following incubation, cells were pelleted and washed 3 times with BSB. The cells were then stained with FITC-conjugated anti-human C3 F(ab′)2 (Protos Immunoresearch; catalog no. 365) at a 1:50 final concentration, washed 3 times with BSB, and stained with a 1:1,000 dilution of SYTO 59 (Molecular Probes) for 1 h at 37°C. Each sample was analyzed using an LSRII flow cytometer, with gating on the top population that appeared on the FSC/SSC plot determined as described earlier. Spectral overlap was calculated from single-stained controls, and a single-cell gate and an APC$^+$ gate were further set using unstained controls. The absolute numbers of events that were APC$^+$ and FITC$^-$ (intact cells that lacked C3 fragments) were plotted on the bar graph for each serum concentration. Student's *t* test was performed to calculate the P value. The histogram was generated by plotting the fluorescence intensity of FITC versus the maximum percentage. Spectral overlap was calculated from single-stationed controls. All post-acquisition analyses and compensations were performed using FlowJo (Tree Star).

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at http://mbio.asm.org/lookup/suppl/doi:10.1128/mBio.01339-15/-/DCSupplemental.

Figure S1, PDF file, 1.3 MB.
Figure S2, PDF file, 0.1 MB.
Figure S3, PDF file, 0.3 MB.
Table S1, PDF file, 0.05 MB.
Table S2, PDF file, 0.03 MB.
Text S1, PDF file, 0.01 MB.
Text S2, PDF file, 0.01 MB.
Text S3, PDF file, 0.01 MB.

REFERENCES

1. **Corbett D, Roberts IS**. 2009. The role of microbial polysaccharides in host-pathogen interaction. F1000 Biol Rep **1**:30. http://dx.doi.org/10.3410/B1-30.

2. **Round JL, Mazmanian SK**. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol **9**:313–323. http://dx.doi.org/10.1038/nri2515.

3. **Mahowald MA, Rey FE, Seedorf H, Turnbaugh PJ, Fulton RS, Wollam A, Shah N, Wang C, Magrini V, Wilson RK, Cantarel BL, Coutinho PM, Henrissat B, Crock LW, Russell A, Verberkmoes NC, Hettich RL, Gordon JI**. 2009. Characterizing a model human gut microbiota composed of members of its two dominant bacterial phyla. Proc Natl Acad Sci U S A **106**:5859–5864. http://dx.doi.org/10.1073/pnas.0901529106.

4. **Turnbaugh PJ, Gordon JI**. 2009. The core gut microbiome, energy balance, and obesity. J Physiol **587**:4153–4158 http://dx.doi.org/10.1113/jphysiol.2009.174136.

5. **Human Microbiome Project Consortium**. 2012. Structure, function and diversity of the healthy human microbiome. Nature **486**:207–214. http://dx.doi.org/10.1038/nature11234.

6. **Mazmanian SK, Round JL, Kasper DL**. 2008. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature **453**:620–625. http://dx.doi.org/10.1038/nature07008.

7. **Krinos CM, Coyne MJ, Weinacht KG, Tzianabos AO, Kasper DL, Comstock LE**. 2001. Extensive surface diversity of a commensal microorganism by multiple DNA inversions. Nature **414**:555–558. http://dx.doi.org/10.1038/35107092.

8. **Coyne MJ, Weinacht KG, Krinos CM, Comstock LE**. 2003. Mpi recombinase globally modulates the surface architecture of a human commensal bacterium. Proc Natl Acad Sci U S A **100**:10446–10451. http://dx.doi.org/10.1073/pnas.1832655100.

9. **Weinacht KG, Roche H, Krinos CM, Coyne MJ, Parkhill J, Comstock LE**. 2004. Tyrosine site-specific recombinases mediate DNA inversions affecting the expression of outer surface proteins of *Bacteroides fragilis*. Mol Microbiol **53**:1319–1330. http://dx.doi.org/10.1111/j.1365-2958.2004.04219.x.

10. **Chatzidaki-Livanis M, Coyne MJ, Comstock LE**. 2009. A family of transcriptional antitermination factors necessary for synthesis of the capsular polysaccharides of *Bacteroides fragilis*. J Bacteriol **191**:7288–7295. http://dx.doi.org/10.1128/JB.00500-09.

11. **Chatzidaki-Livanis M, Weinacht KG, Comstock LE**. 2010. Trans locus inhibitors limit concomitant polysaccharide synthesis in the human gut symbiont *Bacteroides fragilis*. Proc Natl Acad Sci U S A **107**:11976–11980.

12. **Coyne MJ, Chatzidaki-Livanis M, Paoletti LC, Comstock LE**. 2008. Role of glycan synthesis in colonization of the mammalian gut by the bacterial symbiont *Bacteroides fragilis*. Proc Natl Acad Sci U S A **105**:13099–13104. http://dx.doi.org/10.1073/pnas.0804220105.

13. **Coyne MJ, Comstock LE**. 2008. Niche-specific features of the intestinal *Bacteroidales*. J Bacteriol **190**:736–742. http://dx.doi.org/10.1128/JB.01559-07.

14. **Liu CH, Lee SM, VanLare JM, Kasper DL, Mazmanian SK**. 2008. Regulation of surface architecture by symbiotic bacteria mediates host colonization. Proc Natl Acad Sci U S A **105**:3951–3956. http://dx.doi.org/10.1073/pnas.0709266105.

15. **Donia MS, Cimermancic P, Schulze CJ, Wieland Brown LC, Martin J, Mitreva M, Clardy J, Linington RG, Fischbach MA**. 2014. A systematic analysis of biosynthetic gene clusters in the human microbiome reveals a common family of antibiotics. Cell **158**:1402–1414. http://dx.doi.org/10.1016/j.cell.2014.08.032.

16. **Fagan RP, Fairweather NF**. 2014. Biogenesis and functions of bacterial S-layers. Nat Rev Microbiol **12**:211–222. http://dx.doi.org/10.1038/nrmicro3213.

17. **Pumbwe L, Skilbeck CA, Wexler HM**. 2006. The *Bacteroides fragilis* cell envelope: quarterback, linebacker, coach---or all three? Anaerobe **12**:211–220. http://dx.doi.org/10.1016/j.anaerobe.2006.09.004.

18. **Fletcher CM, Coyne MJ, Bentley DL, Villa OF, Comstock LE**. 2007. Phase-variable expression of a family of glycoproteins imparts a dynamic surface to a symbiont in its human intestinal ecosystem. Proc Natl Acad Sci U S A **104**:2413–2418. http://dx.doi.org/10.1073/pnas.0608797104.

19. **Kuwahara T, Yamashita A, Hirakawa H, Nakayama H, Toh H, Okada N, Kuhara S, Hattori M, Hayashi T, Ohnishi Y**. 2004. Genomic analysis of *Bacteroides fragilis* reveals extensive DNA inversions regulating cell sur-

face adaptation. Proc Natl Acad Sci U S A **101:**14919–14924. http://dx.doi.org/10.1073/pnas.0404172101.

20. **Snyder JA, Lloyd AL, Lockatell CV, Johnson DE, Mobley HL.** 2006. Role of phase variation of type 1 fimbriae in a uropathogenic *Escherichia coli* cystitis isolate during urinary tract infection. Infect Immun **74:**1387–1393. http://dx.doi.org/10.1128/IAI.74.2.1387-1393.2006.

21. **Troy EB, Carey VJ, Kasper DL, Comstock LE.** 2010. Orientations of the *Bacteroides fragilis* capsular polysaccharide biosynthesis locus promoters during symbiosis and infection. J Bacteriol **192:**5832–5836. http://dx.doi.org/10.1128/JB.00555-10.

22. **Blaser MJ, Smith PF, Kohler PF.** 1985. Susceptibility of *Campylobacter* isolates to the bactericidal activity of human serum. J Infect Dis **151:**227–235. http://dx.doi.org/10.1093/infdis/151.2.227.

23. **Blaser MJ, Smith PF, Repine JE, Joiner KA.** 1988. Pathogenesis of *Campylobacter fetus* infections. Failure of encapsulated *Campylobacter fetus* to bind C3b explains serum and phagocytosis resistance. J Clin Invest **81:**1434–1444. http://dx.doi.org/10.1172/JCI113474.

24. **Lambris JD, Ricklin D, Geisbrecht BV.** 2008. Complement evasion by human pathogens. Nat Rev Microbiol **6:**132–142. http://dx.doi.org/10.1038/nrmicro1824.

25. **Chehoud C, Rafail S, Tyldsley AS, Seykora JT, Lambris JD, Grice EA.** 2013. Complement modulates the cutaneous microbiome and inflammatory milieu. Proc Natl Acad Sci U S A **110:**15061–15066. http://dx.doi.org/10.1073/pnas.1307855110.

26. **Reinicke AT, Herrmann A, Baer F, Sina C, Srinivas G, Kuenzel S, Baines J, Köhl J.** 2012. C5aR regulates intestinal microbiota composition and controls the induction of gastrointestinal allergic hypersensitivity. Immunobiology **217:**1147. http://dx.doi.org/10.1016/j.imbio.2012.08.052.

27. **Maekawa T, Krauss JL, Abe T, Jotwani R, Triantafilou M, Triantafilou K, Hashim A, Hoch S, Curtis MA, Nussbaum G, Lambris JD, Hajishengallis G.** 2014. *Porphyromonas gingivalis* manipulates complement and TLR signaling to uncouple bacterial clearance from inflammation and promote dysbiosis. Cell Host Microbe **15:**768–778. http://dx.doi.org/10.1016/j.chom.2014.05.012.

28. **Ahrenstedt O, Knutson L, Nilsson B, Nilsson-Ekdahl K, Odlind B, Hällgren R.** 1990. Enhanced local production of complement components in the small intestines of patients with Crohn's disease. N Engl J Med **322:**1345–1349. http://dx.doi.org/10.1056/NEJM199005103221903.

29. **Baklien K, Brandtzaeg P.** 1974. Immunohistochemical localisation of complement in intestinal mucosa. Lancet **304:**1087–1088. http://dx.doi.org/10.1016/S0140-6736(74)92198-9.

30. **Halstensen TS, Brandtzaeg P.** 1991. Local complement activation in inflammatory bowel disease. Immunol Res **10:**485–492. http://dx.doi.org/10.1007/BF02919746.

31. **Halstensen TS, Mollnes TE, Garred P, Fausa O, Brandtzaeg P.** 1992. Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis. Gut **33:**902–908. http://dx.doi.org/10.1136/gut.33.7.902.

32. **Belzer C, Liu Q, Carroll MC, Bry L.** 2011. The role of specific IgG and complement in combating a primary mucosal infection of the gut epithelium. Eur J Microbiol Immunol (Bp) **1:**311–318. http://dx.doi.org/10.1556/EuJMI.1.2011.4.7.

33. **Andoh A, Fujiyama Y, Sakumoto H, Uchihara H, Kimura T, Koyama S, Bamba T.** 1998. Detection of complement C3 and factor B gene expression in normal colorectal mucosa, adenomas and carcinomas. Clin Exp Immunol **111:**477–483. http://dx.doi.org/10.1046/j.1365-2249.1998.00496.x.

34. **Laufer J, Oren R, Goldberg I, Horwitz A, Kopolovic J, Chowers Y, Passwell JH.** 2000. Cellular localization of complement C3 and C4 transcripts in intestinal specimens from patients with Crohn's disease. Clin Exp Immunol **120:**30–37. http://dx.doi.org/10.1046/j.1365-2249.2000.01168.x.

35. **Martens EC, Chiang HC, Gordon JI.** 2008. Mucosal glycan foraging enhances fitness and transmission of a saccharolytic human gut bacterial symbiont. Cell Host Microbe **4:**447–457. http://dx.doi.org/10.1016/j.chom.2008.09.007.

36. **Holdeman LV, Moore WEC.** 1977. Anaerobe laboratory manual. Virginia Polytechnic Institute and State University, Blacksburg, VA.

37. **Koropatkin NM, Martens EC, Gordon JI, Smith TJ.** 2008. Starch catabolism by a prominent human gut symbiont is directed by the recognition of amylose helices. Structure **16:**1105–1115. http://dx.doi.org/10.1016/j.str.2008.03.017.

38. **Gunther NW, Snyder JA, Lockatell V, Blomfield I, Johnson DE, Mobley HL.** 2002. Assessment of virulence of uropathogenic *Escherichia coli* type 1 fimbrial mutants in which the invertible element is phase-locked on or off. Infect Immun **70:**3344–3354. http://dx.doi.org/10.1128/IAI.70.7.3344-3354.2002.

39. **Moyes RB.** 2009. Fluorescent staining of bacteria: viability and antibody labeling. Curr Protoc Microbiol Appendix **3:**Appendix-3K. http://dx.doi.org/10.1002/9780471729259.mca03ks15.